Helen Chow1, Paramita M Ghosh2,3,4, Ralph deVere White4, Christopher P Evans4, Marc A Dall'Era4, Stanley A Yap4, Yueju Li5, Laurel A Beckett5, Primo N Lara1, Chong-Xian Pan1,3,4. 1. Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis, Sacramento, California. 2. Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California. 3. Veterans Affairs Northern California Health Care System-Mather, Mather, California. 4. Department of Urology, University of California Davis, Sacramento, California. 5. Department of Public Health Sciences, University of California, Davis, California.
Abstract
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective in inducing apoptosis in prostate cancer cells, likely because of the compensatory up-regulation of the androgen receptor (AR) pathway. METHODS:Patients who were eligible for this study had to have progressive CRPC with serum testosterone levels <50 ng/dL. No prior bicalutamide (except to prevent flare) or everolimus was allowed. Treatment included oral bicalutamide 50 mg and oral everolimus 10 mg, both once daily, with a cycle defined as 4 weeks. The primary endpoint was the prostate-specific antigen (PSA) response (≥30% reduction) from baseline. A sample size of 23 patients would have power of 0.8 and an α error of .05 (1-sided) if the combination had a PSA response rate of 50% versus a historic rate of 25% with bicalutamide alone. RESULTS:Twenty-four patients were enrolled. The mean age was 71.1 years (range, 53.0-87.0 years), the mean PSA level at study entry was 43.4 ng/dL (range, 2.5-556.9 ng/dL), and the mean length of treatment was 8 cycles (range, 1.0-23.0 cycles). Of 24 patients, 18 had a PSA response (75%; 95% confidence interval [CI], 0.53-0.90), whereas 15 (62.5%; 95% CI, 0.41-0.81) had a PSA decrease ≥50%. The median overall survival was 28 months (95% CI, 14.1-42.7 months). Fourteen patients (54%; 95% CI, 0.37-0.78) developed grade 3 (13 patients) or grade 4 (1 patient with sepsis) adverse events that were attributable to treatment. CONCLUSIONS: The combination of bicalutamide and everolimus has encouraging efficacy in men with bicalutamide-naive CRPC, thus warranting further investigation. A substantial number of patients experienced everolimus-related toxicity. Cancer 2016;122:1897-904.
RCT Entities:
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective in inducing apoptosis in prostate cancer cells, likely because of the compensatory up-regulation of the androgen receptor (AR) pathway. METHODS:Patients who were eligible for this study had to have progressive CRPC with serum testosterone levels <50 ng/dL. No prior bicalutamide (except to prevent flare) or everolimus was allowed. Treatment included oral bicalutamide 50 mg and oral everolimus 10 mg, both once daily, with a cycle defined as 4 weeks. The primary endpoint was the prostate-specific antigen (PSA) response (≥30% reduction) from baseline. A sample size of 23 patients would have power of 0.8 and an α error of .05 (1-sided) if the combination had a PSA response rate of 50% versus a historic rate of 25% with bicalutamide alone. RESULTS: Twenty-four patients were enrolled. The mean age was 71.1 years (range, 53.0-87.0 years), the mean PSA level at study entry was 43.4 ng/dL (range, 2.5-556.9 ng/dL), and the mean length of treatment was 8 cycles (range, 1.0-23.0 cycles). Of 24 patients, 18 had a PSA response (75%; 95% confidence interval [CI], 0.53-0.90), whereas 15 (62.5%; 95% CI, 0.41-0.81) had a PSA decrease ≥50%. The median overall survival was 28 months (95% CI, 14.1-42.7 months). Fourteen patients (54%; 95% CI, 0.37-0.78) developed grade 3 (13 patients) or grade 4 (1 patient with sepsis) adverse events that were attributable to treatment. CONCLUSIONS: The combination of bicalutamide and everolimus has encouraging efficacy in men with bicalutamide-naive CRPC, thus warranting further investigation. A substantial number of patients experienced everolimus-related toxicity. Cancer 2016;122:1897-904.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: H I Scher; C Liebertz; W K Kelly; M Mazumdar; C Brett; L Schwartz; G Kolvenbag; L Shapiro; M Schwartz Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: Mari Nakabayashi; Lilian Werner; Kevin D Courtney; Geoffrey Buckle; William K Oh; Glen J Bubley; Julia H Hayes; Douglas Weckstein; Aymen Elfiky; Danny M Sims; Philip W Kantoff; Mary-Ellen Taplin Journal: BJU Int Date: 2012-08-29 Impact factor: 5.588
Authors: Arun A Azad; Emma K Beardsley; Sebastian J Hotte; Susan L Ellard; Lawrence Klotz; Joseph Chin; Christian Kollmannsberger; Som D Mukherjee; Kim N Chi Journal: Invest New Drugs Date: 2014-03-28 Impact factor: 3.850
Authors: Mitchell E Gross; Tanya B Dorff; David I Quinn; Patricia M Diaz; Olga O Castellanos; David B Agus Journal: Clin Genitourin Cancer Date: 2017-07-14 Impact factor: 2.872
Authors: Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan Journal: Nat Rev Urol Date: 2018-02-20 Impact factor: 14.432
Authors: Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Veit Sandfort; Sanjeewani T Palayoor; Barbara H Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F Petricoin; Matthew F Brown; Jayne M Stommel; Mansoor M Ahmed; C Norman Coleman Journal: Mol Cancer Ther Date: 2017-08-11 Impact factor: 6.009
Authors: L S D'Abronzo; S Bose; M E Crapuchettes; R E Beggs; R L Vinall; C G Tepper; S Siddiqui; M Mudryj; F U Melgoza; B P Durbin-Johnson; R W deVere White; P M Ghosh Journal: Oncogene Date: 2017-07-24 Impact factor: 9.867
Authors: Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech Journal: Nat Rev Urol Date: 2020-03-16 Impact factor: 14.432